The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
It has been suggested, based on rodent studies, that levodopa (L-dopa) induced dyskinesia is associated with a disrupted blood-brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned primates exhibiting L-dopa-induced dyskinesia. Magnetic resonance imaging (MRI) performed before and after injection of Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revealed an intact BBB in the basal ganglia showing that l-dopa-induced dyskinesia is not associated with a disrupted BBB in this model.
Astradsson
Arnar
A
Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence, Belmont, MA 02478, USA.
Jenkins
Bruce G
BG
Choi
Ji-Kyung
JK
Hallett
Penelope J
PJ
Levesque
Michele A
MA
McDowell
Jack S
JS
Brownell
Anna-Liisa
AL
Spealman
Roger D
RD
Isacson
Ole
O
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000473:pathology*; D001921:Brain / Q000098:blood supply / Q000473:pathology; D004409:Dyskinesia, Drug-Induced / Q000473:pathology*; D019786:Gadolinium DTPA; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008252:Macaca fascicularis; D008279:Magnetic Resonance Imaging; D008297:Male; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
D000978:Antiparkinson Agents; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D019786:Gadolinium DTPA